Treatment of solid tumors and metastases by fibrinogen-targeted anticancer drug therapy

Medical Hypotheses

Volumn 68, Issue 1, 2007, Pages 188-193

  Lu, Da Yong ^a   Chen, Xue Liang ^b   Ding, Jian ^c  

^a SHANGHAI UNIVERSITY   (China)

^b Central Hospital of Jing An District   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; DOCETAXEL; FIBRINOGEN; FIBRINOLYTIC AGENT; FLUOROURACIL; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OXALYSINE; PROTEINASE; RETINOIC ACID; SELENITE; UNCLASSIFIED DRUG; UROKINASE; VITAMIN K GROUP; WARFARIN;

ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD TOXICITY; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CLINICAL FEATURE; COLON CANCER; CYTOTOXICITY; HUMAN; KIDNEY CARCINOMA; LABORATORY TEST; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR;

EID: 33750607876     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.06.045     Document Type: Article

References (34)

1. Fidler I.J. Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes memorial award lecture. Cancer Res 50 19 (1990) 6130-6138
2. Zacharski L.R. Anticoagulation in the treatment of cancer in man. In: Donati M.B., Davidson J.E., and Garattinii E. (Eds). Malignancy and hemostatic system (1981), Raven Press, New York 113-128
3. Dvorak H.F. Tumor wounds that do not heal, similarities between tumor stroma generation and wound healing. New Engl J Med 315 26 (1986) 1650-1659
4. Dvorak H.F., Senger D.R., and Dvorak A.M. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev. 2 1 (1983) 41-73
5. Costantini V., and Zacharski L.R. The role of fibrin in tumor metastasis. Cancer Metastasis Rev 11 3 (1992) 283-290
6. Zacharski L.R., Henderson W.G., Rickles F.R., Forman W.B., Cornell C.J., Forcier R.J., et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA cooperative study #75. Cancer 53 10 (1984) 2046-2052
7. Collen A., Smorenburg S.M., Peters E., Lupu F., Koolwijk P., Noorden C.V., et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 60 21 (2000) 6196-6200
8. Smorenburg S.M., and van Noorden C.J.F. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53 1 (2001) 93-105
9. Yue X.F., Wu F.G., and Xu B. Effect of oxalysine on plasma fibrinogen content in tumor-bearing mice. Acta Pharmacol Sin 3 2 (1982) 124-128
10. Yue X.F., Wu F.G., and Xu B. Effects of oxalysine on pulmonary metastasis of Lewis lung carcinoma in mice. Acta Pharmacol Sin 6 3 (1985) 198-200
11. Perides G., Zhuge Y., Lin T., Stins M.F., Bronson R.T., and Wu J.K. The fibrinolytic system facilitates tumor cell migration across the blood- brain barrier in experimental melanoma brain metastasis. BMC Cancer 6 (2006) 56
12. Staton C.A., Brown N.J., Rodgers G.R., Corke K.P., Tazzyman S., Underwood J.C., et al. Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo. Blood 103 2 (2004) 601-606
13. Staton C.A., Brown N.J., and Lewis C.E. The role of fibrinogen and related fragments in tumour angiogenesis and metastasis. Expert Opinion Bio Ther 3 (2003) 1105-1120
14. 125I-fibrinogen to two leukemia cell lines in vitro. J Int Med Res 32 5 (2004) 488-491
15. Sharma P., and Bentley P. Of rats and men: superwarfarin toxicity. Lancet 365 (2005) 552-554
16. Blann A.D., Fitzmaurice D.A., and Lip G.Y.H. Anticoagulation in hospitals and general practice. Br Med J 326 (2003) 153-156
17. Lu D.Y., Cao J.Y., Huang Y.P., Gong L., Chen X.L., Chen E.H., et al. Comparison of some antineoplastic drugs on inhibiting thrombin catalyzing fibrinogen clotting in vitro. Chin Med J (Eng) 112 (1999) 1052-1053
18. Jakate A.S., Einhaus C.M., DeAnglis A.P., Retzinger G.S., and Desai P.B. Preparation, characterization, and preliminary application of fibrinogen-coated olive oil droplets for the targeted delivery of docetaxel to solid malignancies. Cancer Res 63 (2003) 7314-7320
19. Einhaus C.M., Retzinger A.C., Perrotta A.O., Dentler M.D., Jakate A.S., Desai P.B., et al. Fibrinogen-coated droplets of olive for delivery of docetaxel to a fibrin (ogen)-rich ascites form of a murine mammary tumor. Clin Cancer Res 10 (2004) 7001-7010
20. Tallman M.S., Lefebvre P., Baine R.M., Shoji M., Cohen I., Green D., et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2 (2004) 1341-1350
21. Lipinski B. Rationale for the treatment of cancer with sodium selenite. Med Hypotheses 64 4 (2005) 806-810
22. Rybarczyk B.J., and Simpson-Haidaris P.J. Fibrinogen assembly, secretion and deposition into extracellular matrix by MCF-7 human breast carcinoma cells. Cancer Res 60 7 (2000) 2033-2039
23. Palumbo J.S., Potter J.M., Kaplan L.S., Talmage K., Jackson D.G., and Degen J.L. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 62 23 (2002) 6966-6972
24. Lu D.Y., Chen X.L., Cao J.Y., Li Z., Xue H.W., Luo L.J., et al. Effects of cancer chemotherapy on the blood fibrinogen contents of cancer patients. J Int Med Res 28 6 (2000) 313-317
25. Rubel C., Fernandez G.C., Rocsa F.A., Gomez S., Bompadre M.B., Cosa O.A., et al. Soluble fibrinogen modulates neutrophil functionality through the activation of an extracellular signal-regulated kinase-dependent pathway. J Immunol 168 7 (2002) 3527-3535
26. Sadler J.E. K is for koagulation. Nature 427 (2004) 493-494
27. Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hortnagel K., Pelz H.J., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427 (2004) 537-541
28. Li T., Chang C.Y., Jin D.Y., Lin P.J., Khvorova A., and Stafford D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427 (2004) 541-544
29. Lu D.Y., Chen X.L., and Ding J. Individualized cancer chemotherapy integrating drug sensitivity tests, pathological profile analysis and computational coordinating - an effective strategy to improve clinical treatment. Med Hypotheses 66 (2006) 45-51
30. Kyrle P.A., and Eichinger S. Deep vein thrombosis. Lancet 365 (2005) 1163-1174
31. Vanhoorelbeke K., Ulrichts H., Schoolmeester A., and Deckmyn H. Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs. Curr Drug Targets - Cardiovascular Haematol Disorders 3 (2003) 125-140
32. Kearon C., Ginsberg J.S., Kovacs M.J., Anderson D.R., Wells P., Julian J.A., et al. Comparison of low-intensity warfarin therapy with conventional- intensity warfarin therapy for long- term prevention of recurrent venous thromboembolism. New Engl J Med 349 7 (2003) 631-639
33. Linkins L.A., and Weitz J.I. An update on new anticoagulants. Curr Drug Targets - Cardiovascular Haematol Disorders 3 4 (2003) 287-300
34. Eikelboom T.M., Mehta S.R., Hughes-Davies T.H., Roychowdhury D., Zacharski L.R., and Lindemarker P. Venous thromboembolism and cancer. New Engl J Med 343 18 (2000) 1337-1338